162 related articles for article (PubMed ID: 37638009)
1. Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level.
Liu MK; Liu F; Dai YT; Weng XQ; Cheng LL; Fan LQ; Liu H; Jiang L; Sun XJ; Fang H; Wang L; Zhao WL
Front Immunol; 2023; 14():1210909. PubMed ID: 37638009
[TBL] [Abstract][Full Text] [Related]
2. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Jawhar M; Schwaab J; Meggendorfer M; Naumann N; Horny HP; Sotlar K; Haferlach T; Schmitt K; Fabarius A; Valent P; Hofmann WK; Cross NCP; Metzgeroth G; Reiter A
Haematologica; 2017 Jun; 102(6):1035-1043. PubMed ID: 28255023
[TBL] [Abstract][Full Text] [Related]
3. Mast cell leukemia with prolonged survival on PKC412/midostaurin.
Xu X; Kreisel FH; Frater JL; Hassan A
Int J Clin Exp Pathol; 2014; 7(6):3439-43. PubMed ID: 25031773
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
[TBL] [Abstract][Full Text] [Related]
5. From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia.
Decker J; Meyer S; Latger-Cannard V; Visanica S; Loppinet E; Lesesve JF; Bénet B
Ann Biol Clin (Paris); 2017 Dec; 75(6):689-694. PubMed ID: 29043985
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
7. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
[TBL] [Abstract][Full Text] [Related]
9. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
[TBL] [Abstract][Full Text] [Related]
10. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
11. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
14. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
Zheng Y; Nong L; Liang L; Wang W; Li T
Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
[TBL] [Abstract][Full Text] [Related]
15. Clinical potential of midostaurin in advanced systemic mastocytosis.
Chandesris MO; Damaj G; Lortholary O; Hermine O
Blood Lymphat Cancer; 2017; 7():25-35. PubMed ID: 31360083
[TBL] [Abstract][Full Text] [Related]
16. Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis.
Szudy-Szczyrek A; Bachanek-Mitura O; Gromek T; Chromik K; Mital A; Szczyrek M; Krupski W; Szumiło J; Kanduła Z; Helbig G; Hus M
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33799933
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
18. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Gleixner KV; Mayerhofer M; Aichberger KJ; Derdak S; Sonneck K; Böhm A; Gruze A; Samorapoompichit P; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Blood; 2006 Jan; 107(2):752-9. PubMed ID: 16189265
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
20. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]